Comparative Pharmacology
Head-to-head clinical analysis: AMPHETAMINE SULFATE versus XELSTRYM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPHETAMINE SULFATE versus XELSTRYM.
AMPHETAMINE SULFATE vs XELSTRYM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases presynaptic release of dopamine and norepinephrine, blocks reuptake, and inhibits monoamine oxidase, resulting in CNS stimulation.
XELSTRYM (dextroamphetamine transdermal system) is a sympathomimetic amine that increases synaptic concentrations of dopamine and norepinephrine by inhibiting their reuptake and promoting their release from presynaptic terminals.
5–60 mg/day orally in 1–3 divided doses, initial 5 mg once or twice daily, increase by 5 mg weekly.
Initial: one 9-mg patch applied to the hip once daily; titrate weekly in 4.5-mg increments to desired effect; maximum dose: 18 mg/day.
None Documented
None Documented
Terminal elimination half-life: 10-13 hours in adults with acidic urine; prolonged to 16-34 hours with alkaline urine. In children, half-life is typically shorter (6-8 hours).
Mean terminal elimination half-life of dexmethylphenidate is approximately 2-3 hours in children and adolescents, with no significant accumulation at steady state; clinical effects correlate with plasma concentrations.
Renal excretion of unchanged amphetamine (approximately 30-40%) and its metabolites; urinary pH-dependent: acidic urine enhances elimination (up to 70% unchanged), alkaline urine reduces it. Minor biliary/fecal elimination (<10%).
Renal (90% as unchanged drug and metabolites, primarily dehydrodexmethylphenidate and inactive metabolites); minor biliary/fecal elimination (<5%)
Category D/X
Category C
CNS Stimulant
CNS Stimulant